351P Sevasemten, a fast myosin inhibitor, in adults with Becker muscular dystrophy results in reduced muscle damage biomarkers and functional stabilization
J. Donovan, James E. MacDougall(BioBridges (United States)), Maria Pia Amato(University of Florence), A. Russell, B. Barthel, H. Phan(Rare Disease Therapeutics (United States)), L. Thaler(Emory University), N. Kilburn
Cited by 2
Related Papers
Hyperglycemia: An Independent Marker of In-Hospital Mortality in Patients with Undiagnosed Diabetes
|The Journal of Clinical Endocrinology & Metabolism|2002|2.1k
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706
Multiple sclerosis progression: time for a new mechanism-driven framework
|The Lancet Neurology|2022|624
Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis
|The Lancet Neurology|2015|523